Literature DB >> 18565399

Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.

Katherine C Wu1, Robert G Weiss, David R Thiemann, Kakuya Kitagawa, André Schmidt, Darshan Dalal, Shenghan Lai, David A Bluemke, Gary Gerstenblith, Eduardo Marbán, Gordon F Tomaselli, João A C Lima.   

Abstract

OBJECTIVES: We examined whether the presence and extent of late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) predict adverse outcomes in nonischemic cardiomyopathy (NICM) patients.
BACKGROUND: Morbidity and mortality is high in NICM patients. However, the clinical course of an individual patient is unpredictable and current risk stratification approaches are limited. Cardiovascular magnetic resonance detects myocardial fibrosis, which appears as LGE after contrast administration and may convey prognostic importance.
METHODS: In a prospective cohort study, 65 NICM patients with left ventricular (LV) ejection fraction < or =35% underwent CMR before placement of an implantable cardioverter-defibrillator (ICD) for primary prevention of sudden cardiac death. The CMR images were analyzed for the presence and extent of LGE and for LV function, volumes, and mass. Patients were followed for an index composite end point of 3 cardiac events: hospitalization for heart failure, appropriate ICD firing, and cardiac death.
RESULTS: A total of 42% (n = 27) of patients had CMR LGE, averaging 10 +/- 13% of LV mass. During a 17-month median follow-up, 44% (n = 12) of patients with LGE had an index composite outcome event versus only 8% (n = 3) of those without LGE (p < 0.001 for Kaplan-Meier survival curves). After adjustment for LV volume index and functional class, patients with LGE had an 8-fold higher risk of experiencing the primary outcome (hazard ratio 8.2, 95% confidence interval 2.2 to 30.9; p = 0.002).
CONCLUSIONS: A CMR LGE in NICM patients strongly predicts adverse cardiac outcomes. The CMR LGE may represent the end-organ consequences of sustained adrenergic activation and adverse LV remodeling, and its identification may significantly improve risk stratification strategies in this high risk population. (Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk; NCT00181233).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565399      PMCID: PMC2459322          DOI: 10.1016/j.jacc.2008.03.018

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

1.  Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy.

Authors:  N de Leeuw; D J Ruiter; A H Balk; N de Jonge; W J Melchers; J M Galama
Journal:  Transpl Int       Date:  2001-09       Impact factor: 3.782

2.  An improved MR imaging technique for the visualization of myocardial infarction.

Authors:  O P Simonetti; R J Kim; D S Fieno; H B Hillenbrand; E Wu; J M Bundy; J P Finn; R M Judd
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

3.  A standardized definition of ischemic cardiomyopathy for use in clinical research.

Authors:  G Michael Felker; Linda K Shaw; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

4.  Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction.

Authors:  André Schmidt; Clerio F Azevedo; Alan Cheng; Sandeep N Gupta; David A Bluemke; Thomas K Foo; Gary Gerstenblith; Robert G Weiss; Eduardo Marbán; Gordon F Tomaselli; João A C Lima; Katherine C Wu
Journal:  Circulation       Date:  2007-03-26       Impact factor: 29.690

5.  Mapping and radiofrequency catheter ablation of the three types of sustained monomorphic ventricular tachycardia in nonischemic heart disease.

Authors:  E Delacretaz; W G Stevenson; K E Ellison; W H Maisel; P L Friedman
Journal:  J Cardiovasc Electrophysiol       Date:  2000-01

Review 6.  Characterization of the electroanatomic substrate for monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy.

Authors:  Henry H Hsia; Francis E Marchlinski
Journal:  Pacing Clin Electrophysiol       Date:  2002-07       Impact factor: 1.976

7.  Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy.

Authors:  David Bello; Dipan J Shah; George M Farah; Silvia Di Luzio; Michele Parker; Maryl R Johnson; William G Cotts; Francis J Klocke; Robert O Bonow; Robert M Judd; Mihai Gheorghiade; Raymond J Kim
Journal:  Circulation       Date:  2003-10-13       Impact factor: 29.690

8.  Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II).

Authors:  Henry Greenberg; Robert B Case; Arthur J Moss; Mary W Brown; Elizabeth R Carroll; Mark L Andrews
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

9.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

10.  Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance.

Authors:  J A McCrohon; J C C Moon; S K Prasad; W J McKenna; C H Lorenz; A J S Coats; D J Pennell
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

View more
  180 in total

1.  Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death.

Authors:  Katherine C Wu; Gary Gerstenblith; Eliseo Guallar; Joseph E Marine; Darshan Dalal; Alan Cheng; Eduardo Marbán; João A C Lima; Gordon F Tomaselli; Robert G Weiss
Journal:  Circ Cardiovasc Imaging       Date:  2012-01-20       Impact factor: 7.792

2.  Delayed enhancement cardiac magnetic resonance imaging in propionic acidemia.

Authors:  Satoru Iwashima; Takamichi Ishikawa; Takehiko Ohzeki; Yusaku Endou
Journal:  Pediatr Cardiol       Date:  2010-05-19       Impact factor: 1.655

Review 3.  Current and future role of cardiovascular magnetic resonance in cardiac resynchronization therapy.

Authors:  Francisco Leyva; Paul W X Foley
Journal:  Heart Fail Rev       Date:  2011-05       Impact factor: 4.214

Review 4.  Sudden Cardiac Death Substrate Imaged by Magnetic Resonance Imaging: From Investigational Tool to Clinical Applications.

Authors:  Katherine C Wu
Journal:  Circ Cardiovasc Imaging       Date:  2017-07       Impact factor: 7.792

5.  Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging.

Authors:  Ntobeko B A Ntusi; Ashley Chin
Journal:  Eur Radiol       Date:  2008-12-16       Impact factor: 5.315

Review 6.  Role of cardiac MRI in diabetes.

Authors:  Ravi V Shah; Siddique A Abbasi; Raymond Y Kwong
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

Review 7.  The prognostic value of late gadolinium enhancement CMR in nonischemic cardiomyopathies.

Authors:  Theodoros D Karamitsos; Stefan Neubauer
Journal:  Curr Cardiol Rep       Date:  2013-01       Impact factor: 2.931

8.  Role of risk stratification after myocardial infarction.

Authors:  Vikas Kuriachan; Derek V Exner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02

9.  Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance.

Authors:  Javier E Lopez; Khung Yeo; Gary Caputo; Michael Buonocore; Saul Schaefer
Journal:  J Cardiovasc Magn Reson       Date:  2009-11-11       Impact factor: 5.364

10.  Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.

Authors:  Da-Jun Hu; Jing Xu; Wei Du; Jian-Xin Zhang; Min Zhong; Ya-Nan Zhou
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-26       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.